In contrast to untreated patients or patients who did not react to therapy, pemphigus patients who responded to treatment with the B cell-depleting agent rituximab had higher frequencies of CD24hiCD38hi B cells and IL-10 production (198). Here, IL10 is linked to pemphigus.